Drug Giant Pfizer to Build $100 Million R&D Center in Boston
06/13/2011
The new world headquarters for the Centers for Therapeutic Innovation will house 40 employees and Pfizer's drug-development activity, and complement the company's existing offices in Cambridge.
Work at the facility will be done in collaboration with various renowned Boston-based medical and research centers. They include: the University of Massachusetts Medical School, Tufts Medical School, Beth Israel Deaconess Medical Center, Children's Hospital Boston, Partners Healthcare, Harvard University, Boston University and Tufts University. Pfizer indicated in a press release these partners could earn "milestone payments" for successful development of the "next generation of medicines."
"These partnerships allow leading medical and clinical experts to join with Pfizer's highly-skilled scientists and advanced drug development capabilities to speed the translation of innovative science into medicines for patients," said Jose Carlos Gutierrez-Ramos, Ph.D., senior VP and head of BioTherapeutics Research and Development for Pfizer. "Our ultimate goal is to bridge the gap between scientific discovery and the delivery of promising candidates to the pipeline."
Project Announcements
Electric Research and Manufacturing Cooperative Plans Waddell, Arizona, Transformer Production Operations
01/23/2026
Viking Attachments Expands Morgan City, Louisiana, Manufacturing Operations
01/23/2026
France-Based Reju Plans Rochester, New York, Textile Regeneration Operations
01/23/2026
Heil Trailer International Expands Athens, Tennessee, Manufacturing Operations
01/23/2026
Ampirical Expands Covington, Louisiana, Operations
01/23/2026
Laser Isotope Separation Technologies Plans Oak Ridge, Tennessee, Uranium Enrichment Operations
01/22/2026
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Data Centers in 2025: When Power Became the Gatekeeper
Q4 2025
-
Speed Built In—The Real Differentiator for 2026 Site Selection Projects
Q1 2026
-
Preparing for the Next USMCA Shake-Up
Q4 2025
-
Tariff Shockwaves Hit the Industrial Sector
Q4 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
The New Industrial Revolution in Biotech
Q4 2025